Skip to main content

Advertisement

SpringerLink
Log in

Association of p53 and mdm2 in the development and progression of non-small cell lung cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

MDM2 protein is an important regulator of the p53 pathway and has a large effect on the anti-tumorigenic activity of the p53. Presently, we aimed to analyze the possible association of p53 and mdm2 in the development and progression of non-small cell lung cancer. In addition, impact of an important gene promoter polymorphism of MDM2 (T309G, rs 2279744) on its gene expression and ultimately of the TP53 was investigated in non-small cell lung cancer patients. A case–control study using peripheral blood samples of 100 non-small cell lung cancer patients and 100 cancer free healthy controls was conducted. Expression profile of MDM2 and TP53 gene were evaluated by using quantitative real time polymerase chain reaction assay, and MDM2 promoter polymorphism were analyzed by amplification refractory mutation system polymerase chain reaction. Non-small cell lung cancer patients expressed more than 6-fold increased mdm2 and about 7-folds decreased in p53 expression levels compared to healthy controls. Higher fold change increase of mdm2 and/or decrease of p53 were associated with advanced status and poor clinical outcome of the patients. A significant increase in mdm2 of about 14-folds and decrease in p53 of about 16.5-fold were observed among patients with MDM2 (309GG) genotype vs just 2.2-fold increase in mdm2 and 1.9-fold decrease in p53 among patients with MDM2 (309TT) genotype. In conclusion, present study demonstrated that MDM2 (309 T > G) polymorphism may be one of the important factors for the increased expression mdm2, which was associated with down-regulation of p53 at messenger RNA (mRNA) level and ultimately may contribute in the poor clinical outcome of the non-small cell lung cancer patients, thus may prove as a promising target for the treatment of non-small cell lung cancer at molecular level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

MDM2:

Mouse double minute 2 homologue

ARMS:

Amplification refractory mutation system

NSCLC:

Non-small cell lung cancer

SCC:

Squamous cell carcinoma

ADC:

Adenocarcinoma

References

  1. Estimated cancer incidence, mortality and prevalence Worldwide in 2012.GLOBOCAN 2012. http://globocan.iarc.fr/Default.aspx.

  2. Prabhat SM, Mehar CS, Bidhu KM, Shukla NK, Deo SVS, Anant M, et al. Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev. 2013;14(1):489–94.

    Article  Google Scholar 

  3. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5:27–41.

    Article  CAS  PubMed  Google Scholar 

  4. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123–9.

    Article  CAS  PubMed  Google Scholar 

  5. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:983–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Olsson H, Hultman P, Rosell J, Soderkvist P, Jahnson S. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 2013;13:5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhang GX, Li YQ, Pan XL. Polymorphism of MDM2 promoter, regulated by helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility to gastric carcinoma and poor prognosis in Chinese patients. J Gastroenterol Hepatol. 2011;26:280.

    Google Scholar 

  8. Mohan A, Guleria R, Pathak AK, Bhutani M, Pal H, Charu M, et al. Quality of life measures in lung cancer. Ind J Cancer. 2005;42:125–32.

    Article  Google Scholar 

  9. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;27:110–7.

    Article  PubMed  Google Scholar 

  10. Weglarz L, Molin I, Orchel A, Parfiniewicz B, Dzierzewicz Z. Quantitative analysis of the level of p53 and p21WAF1 mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate. Acta Biochim Pol. 2006;53:349–56.

    CAS  PubMed  Google Scholar 

  11. Xiao M, Zhang L, Zhu X, Huang J, Jiang H, Hu S, et al. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer. 2010;10:147.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Shi D, Gu W. Dual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 2012;3(3–4):240–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.

    Article  CAS  PubMed  Google Scholar 

  14. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997;11:1974–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wadgaonkar R, Collins T. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J Biol Chem. 1999;274:13760–7.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000;6:393–416.

    Article  CAS  PubMed  Google Scholar 

  17. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol. 1998;153(6):1749–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996;180:129–37.

    Article  CAS  PubMed  Google Scholar 

  19. Aikawa H, Sato M, Fujimura S, Takahashi H, Endo C, Sakurada A, et al. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med. 2000;5:631–3.

    CAS  PubMed  Google Scholar 

  20. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer. 2004;43(3):285–95.

    Article  PubMed  Google Scholar 

  21. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995;13:1893–903.

    Article  CAS  PubMed  Google Scholar 

  22. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G. Nelson LT relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum. 1994;37(6):527–34.

    Article  CAS  PubMed  Google Scholar 

  23. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn Jr PA, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58(6):1149–58.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors specially thank all of the patients who participated in this study.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Cancer Genetics Lab, Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India

    Jamsheed Javid, P. C. Ray & Alpana Saxena

  2. Division of Molecular Genetics, Prince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia

    Rashid Mir

  3. Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India

    P. K. Julka

Authors
  1. Jamsheed Javid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rashid Mir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. K. Julka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. C. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alpana Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alpana Saxena.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Javid, J., Mir, R., Julka, P.K. et al. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer. Tumor Biol. 36, 5425–5432 (2015). https://doi.org/10.1007/s13277-015-3208-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3208-6

Keywords

Search

Navigation